Prolonged but fruitless efforts to get regulators on the firm’s side seem to have exhausted Ripple’s patience as it eyes a potential IPO and fights a lawsuit.

You might also be interested in reading Halozyme projects $1.15B-$1.225B revenue for 2025 with growth from key products.